BioNexus Gene Lab Corp. Payments for Purchase of Other Assets
BioNexus Gene Lab Corp. (BGLC) reported Payments for Purchase of Other Assets of $9.50 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForPurchaseOfOtherAssets1 · last filed 2026-04-14
- BioNexus Gene Lab Corp. payments for purchase of other assets for the quarter ending 2025-12-31 was $99.00, a 97.50% decline year-over-year.
- BioNexus Gene Lab Corp. payments for purchase of other assets for the quarter ending 2025-09-30 was $7.23K, a 96.24% decline year-over-year.
- BioNexus Gene Lab Corp. payments for purchase of other assets for the quarter ending 2025-06-30 was $2.31K, a 91.98% decline year-over-year.
- BioNexus Gene Lab Corp. payments for purchase of other assets for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- BioNexus Gene Lab Corp. payments for purchase of other assets for fiscal 2025 was $9.50K, a 96.81% decline from fiscal 2024.
- BioNexus Gene Lab Corp. payments for purchase of other assets for fiscal 2024 was $297.74K, a 61.43% increase from fiscal 2023.
- BioNexus Gene Lab Corp. payments for purchase of other assets for fiscal 2023 was $184.43K.
| Period end | Payments for Purchase of Other Assets 3 month | Payments for Purchase of Other Assets 6 month | Payments for Purchase of Other Assets 9 month | Payments for Purchase of Other Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $99.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $7.33K derived: sum of 2 quarters · filed 2026-04-14 | $9.64K derived: sum of 3 quarters · filed 2026-04-14 | $9.50K 10-K · filed 2026-04-14 |
| 2025-09-30 | $7.23K 10-Q · filed 2025-11-14 | $9.54K derived: sum of 2 quarters · filed 2025-11-14 | $9.40K 10-Q · filed 2025-11-14 | $13.51K derived: sum of 4 quarters · filed 2026-04-14 |
| 2025-06-30 | $2.31K 10-Q · filed 2025-08-18 | $2.31K 10-Q · filed 2025-08-18 | $6.27K derived: sum of 3 quarters · filed 2026-04-14 | $198.44K derived: sum of 4 quarters · filed 2026-04-14 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $3.97K derived: sum of 2 quarters · filed 2026-04-14 | $196.14K derived: sum of 3 quarters · filed 2026-04-14 | $224.90K derived: sum of 4 quarters · filed 2026-04-14 |
| 2024-12-31 | $3.97K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $196.14K derived: sum of 2 quarters · filed 2026-04-14 | $224.90K derived: sum of 3 quarters · filed 2026-04-14 | $297.74K 10-K · filed 2026-04-14 |
| 2024-09-30 | $192.17K 10-Q · filed 2025-11-14 | $220.94K derived: sum of 2 quarters · filed 2025-11-14 | $293.77K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $28.77K 10-Q · filed 2025-08-18 | $105.98K 10-Q · filed 2025-08-18 | ||
| 2024-03-31 | $77.21K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $184.43K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |